Intravitreal Bevacizumab for Diabetic Macular Edema
Data Collection
Cardiovascular Diseases+9
+ Diabetes Mellitus
+ Diabetic Angiopathies
Summary
Diabetic macular edema is a common cause of visual loss among diabetic patients. Studies have demonstrated the role of vascular endothelial growth factor (VEGF) in the pathogenesis of edema. This study designed to evaluate the effect of Intravitreal injection of a recombinant monoclonal anti-VEGF antibody, Bevacizumab, for treatment of diabetic macular edema.
Protocol
This section provides details of the study plan, including how the study is designed and what the study is measuring.Eligibility
Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.Any sex
Biological sex of participants that are eligible to enroll.Healthy volunteers not allowed
If individuals who are healthy and do not have the condition being studied can participate.Conditions
Pathology
Criteria
Inclusion Criteria: * Diabetes mellitus * Clinically significant macular edema * Possibility of performing macular OCT * Consent of patient for inclusion in the study Exclusion Criteria: * History of macular photocoagulation in less than 6 months of inclusion in the study * Necessity of surgical intervention * Rejection of the remaining in the study by patient